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Abstract
Purpose This study assessed the incidence of malnutrition
caused by preoperative chemoradiotherapy (CRT) in rectal
cancer patients, which is seemingly underestimated; however,
malnutrition affects treatment tolerability, postoperative com-
plications, including anastomotic leakage (AL), and oncolog-
ical outcomes.
Methods Between January 2008 and December 2014, 54 con-
secutive patients with T3–4, N0–2, M0–1 resectable rectal
cancer received CRT comprising 45 Gy radiotherapy and
S-1 alone or with irinotecan for 5 weeks and then underwent
curative surgery with diverting or permanent stomas 6–
8 weeks after CRT. We assessed malnutrition after completion
of CRT (5–6 weeks after CRT start date) and at surgery (11–
14weeks after CRTstart date), defining weight loss as ≥5% of
pre-CRT weight; this definition differs from commonly used
criteria for adverse events. We evaluated the incidence of mal-
nutrition associated with CRT and influence of malnutrition
on treatment tolerability, AL, and disease-free survival (DFS).
We also assessed the influence of CRT on the rate of postop-
erative complications by comparing the study group with 61
patients who had undergone excision with diverting or perma-
nent stomas alone.
Results Malnutrition was observed in 51 % of patients after
CRT and in 29 % at surgery. Malnutrition after CRT was
associated with treatment tolerability, and malnutrition at
surgery was significantly associated with AL, which signifi-
cantly influenced DFS in stage 1–3 patients.
Conclusion Malnutrition caused by CRT is common and is
associated with treatment tolerability and AL. Nutritional as-
sessment and support seem indispensable for the rectal cancer
patients receiving CRT.
Keywords Malnutrition . Rectal cancer .
Chemoradiotherapy . Anastomotic leakage
Introduction
Colorectal cancer is one of the most common malignancies
worldwide and is the second most common malignancy in
Japan [1]. In Western countries, preoperative chemoradiother-
apy (CRT) is the standard therapy for reducing the risk of local
recurrence in rectal cancer [2]. Common adverse effects of
CRT include hematological toxicities, diarrhea, appetite loss,
and surgical site infection (SSI), including anastomotic leak-
age (AL). However, the relationship between CRT and SSI
remains unclear [3–5].
Malnutrition has been recognized as a risk factor for post-
operative complications, especially infections, including SSI
and AL [6]. Nutritional status affects both treatment tolerabil-
ity and survival in gastrointestinal cancer patients; however,
the incidence of malnutrition is underestimated [7, 8]. The
American Society for Parenteral and Enteral Nutrition guide-
lines do not recommend routine support therapy during anti-
cancer treatment, and European Society for Clinical Nutrition
and Metabolism (ESPEN) guidelines recommend nutritional
support only for patients with malnutrition [9, 10]. The use-
fulness of nutritional intervention in cancer patients treated
with radiotherapy (RT) remains controversial [11–14]. In
* Tomoki Yamano
yamanot@hyo-med.ac.jp
1 Division of Lower GI Surgery, Department of Surgery, Hyogo
College of Medicine, 1-1 Mukogawa-cho,
Nishinomiya, Hyogo 663-8501, Japan
Int J Colorectal Dis (2016) 31:877–884
DOI 10.1007/s00384-016-2507-8
patients with head and neck or esophageal cancer, CRT has
been found to worsen nutritional status; the value of nutrition-
al intervention in these cases is currently being assessed [15].
In rectal cancer patients, malnutrition caused by CRT is not
recognized as a common adverse effect requiring nutritional
support, although CRT is usually more toxic than RT alone.
This is likely because grade 3 weight loss as defined by the
Common Terminology Criteria for Adverse Events (CTCAE)
version 4.0 is weight loss of 20 %, which is unlikely to occur
in only 1 month of CRT treatment [16]. The malnutrition
screening tool (MUST) and nutrition risk screening (NRS)
adopt thresholds of 5 % or more weight loss in 3 months as
indicators of malnutrition [17, 18].
Therefore, we evaluated the incidence of malnutrition by
CRTat two different time points: after completion of CRTand
at surgery, by criteria other than the CTCAE criteria (weight
loss; threshold of 5 % or more). Other nutritional indicators,
body mass index (BMI), serum albumin concentrations, and
NRSwere also assessed. The associations ofmalnutritionwith
treatment tolerability, SSI including AL, and disease-free sur-
vival (DFS) were evaluated.
We also assessed the influence of CRT on postoperative
complications by comparing the study group with 61 rectal
cancer patients who received curative surgery with permanent
or diverting stomas without CRT during the same time period.
Patients and methods
Patients
Between June 2009 and December 2014, consecutive patients
who were diagnosed clinically with T3 or T4, N0–2, M0–1a
(resectable liver metastasis) rectal cancer were recommended
to undergo CRT before surgery. Fifty-four patients consented
to CRTcomprising 45 Gy (25 fractions of 1.8 Gy on days 1–5,
8–12, 15–19, 22–26, and 29–33) in conjunction with S-1
(80 mg/m2 on days 1–5, 8–12, 22–26, and 29–33) and
irinotecan (40–90 mg/m2 on days 1, 8, 22, and 29). Six to
8 weeks after the completion of CRT, total mesorectal excision
with diverting stoma or permanent colostomy was performed
on all patients. This protocol, which is based on that described
by Sato et al., is the same procedure as that used in the S-1
combined preoperative neoadjuvant Multimodality therapy
with Radiation and Irinotecan for locally advanced rectal can-
c e r ( SAMRA I ) - 1 t r i a l a n d SAMRA I - 2 t r i a l
(UMIN000001639 and UMIN000011115, respectively) [19].
To assess the influence of CRT on postoperative complica-
tions, the study patients’ data were compared with those of
61 patients who underwent the Miles operation, Hartmann
operation, or low anterior resection/intersphincter resection
with diverting stomas according to the individual surgeon’s
judgments to minimize complications related to AL during the
same time period. These 61 patients consisted of those who
were not eligible for CRT or those who refused CRT. They
were considered as a high-risk group for postoperative com-
plications. All patients were histologically confirmed to have
rectal adenocarcinoma before commencing treatment. The di-
agnoses were based on clinical examination and the results of
pelvic magnetic resonance imaging and chest/abdominal com-
puted tomography (CT) data. Data collected included clinical
and pathological features, adverse effects during CRT, periop-
erative complications, and prognosis. Pathological features
were classified according to the seventh edition of the
American Joint Committee on Cancer/tumor node metastasis
system. Patients with complete preoperative responses were
classified as stage 0. Among 54 patients, five patients were
excluded from analysis because they were enrolled in the
SAMRAI-2 trial, in which nutritional assessment was one of
the secondary endpoints. One patient received S-1 alone be-
cause of general fatigue that would have been exacerbated by
CRT that included irinotecan. Informed consent was obtained
from all included patients and the Medical Ethics Committee
of the hospital approved this study. Follow-up information on
postoperative recurrence and survival was obtained by mail
for patients who were followed up elsewhere. DFS was de-
fined as time (in months) from surgery to the first evidence of
any further malignancy, death, or last follow-up with no
events (for censored patients). The mean and median dura-
tions of follow-up were 37.8 and 36 months, respectively.
Nutritional assessment
Serum albumin concentrations were measured using routine
methods. Height was routinely measured in all patients, and
weight was measured using a digital scale. Body weight and
serum albumin concentrations were measured at three differ-
ent time points (before CRT, after CRT, and at surgery) for
CRT(+) patients and at surgery for CRT(−) patients. The time
point of Bon consultation^ means before CRT in CRT(+) pa-
tients or at surgery in CRT(−) patients. BMI was calculated as
weight/height2 (kg/m2). Patients were classified according to
the World Health Organization criteria as follows: under-
weight (BMI<18.5), normal weight (18.5≤BMI<25), over-
weight (25≤BMI<30), and obese (BMI≥30). NRS before
CRT, after CRT, and at surgery was calculated according to
the ESPEN guidelines [10]. The duration of CRTwas approx-
imately 5 to 6 weeks, and the period between the start of CRT
and surgery approximately 3 months. Malnutrition was con-
sidered as weight loss of ≥5 % after CRT or at surgery, com-
pared with the patient’s weight before CRT.
Dose intensity of chemotherapy and event monitoring
Dose intensity was calculated as the ratio of the total dosage
administered to patients to that scheduled during CRT, which
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was 1600 mg/m2 for S-1 and 240 mg/m2 for irinotecan.
Receipt of scheduled doses of both S-1 and irinotecan
(100 % or more) was categorized as Bcomplete^ dose
intensity.
Adverse effects of CRT such as hematological and non-
hematological toxicities were recorded and graded according
to the CTCAE version 4.0. All patients were followed up for
more than 30 days after surgery to assess morbidity. The di-
agnosis of SSI was based on the definition in Japan nosoco-
mial infections surveillance guidelines [20]. AL was con-
firmed using CT or contrast enema upon presentation with
clinical symptoms, which included abdominal pain, fever,
and leukocytosis. Some asymptomatic patients were found
to have AL by routine contrast enema 5–7 days after surgery.
Statistical analysis
Statistical analyses were performed using JMP version 11
(SAS Japan Inc., Tokyo, Japan). The influence of CRT on
clinical characteristics, including BMI, serum albumin, NRS,
SSI, and AL, was assessed using a two-sided t test or the χ2
test. The relationships between malnutrition after CRT or at
surgery and side effects, dose intensity, and efficacy of CRT
were assessed using the χ2 test. Nutritional indicators and
other factors that have previously been reported to have an
association with AL were analyzed in the 86 patients who
received surgery with anastomosis using univariate and mul-
tivariate analyses with a logistic regression model [3–5]. DFS
was also assessed in 76 patients who received surgery with
anastomosis and were classified as having stage 1–3 disease,




Patient characteristics are summarized in Table 1. There were
no significant differences in sex, age, presence of diabetes
mellitus, distance from the anal verge, blood loss, operation
time, and incidence of SSI between CRT(+) patients and
CRT(−) patients. CRT(+) patients were more likely to take
steroids and have a smoking habit. CRT(−) patients were more
likely to be classified as category 3 on the American Society
of Anesthesiologists Physical Status criteria, but were less
likely to receive anastomosis with surgery. The proportion of
stages also differed between CRT(+) and CRT(−) patients;
there were more stage 0 or 2 patients in the CRT(+) than the
CRT(−) group, perhaps because CRT resulted in downstaging
of some patients. We consider that these differences between
CRT(+) and CRT(−) patients were inevitable, because this
study retrospectively, but not prospectively, enrolled CRT(−)
patients who had stomas during the study period. Because
CRT(− ) pa t ient s had high Amer ican Socie ty of
Anesthesiologists scores and were therefore considered at
high risk of postoperative complications, diverting stomas
were constructed to reduce complications related to anasto-
motic leakage. Therefore, we could not conclude from our
data that CRT increases the incidence of anastomotic leakage.
A complete response was achieved in six of the 49 patients
(12 %) who received CRT. Four CRT(+) patients had stage 4
disease: two received CRT because they had resectable liver
metastases, and the remaining two were diagnosed as having
unresectable distant lymph node metastases or resectable liver
metastases after CRT. The three with liver metastases subse-
quently underwent liver resection.
Changes in nutritional status
There were no significant differences in BMI, albumin con-
centrations, and the proportion of patients with NRS ≥3 be-
tween CRT(+) and CRT(−) patients on consultation. However,
BMI and albumin concentrations were significantly lower and
the proportion of patients with NRS ≥3 was greater in the
CRT(+) group. Although albumin concentrations at surgery
had recovered to those before CRT, BMI at surgery was still
significantly lower than that before CRT (Table 1). There were
still more patients with NRS ≥3 at surgery than there had been
before CRT; however, the proportion of patients with NRS ≥3
did not differ significantly between CRT(+) and CRT(−)
patients.
Because the usefulness of routine nutritional intervention
for patients receiving preoperative CRT has not yet been
shown, routine nutritional interventions were not implement-
ed except in one patient who requested oral supplementation.
Four patients with grade 3 adverse effects received peripheral
intravenous nutrition to relieve their symptoms.
Figure 1 shows the changes in weight loss after CRTand at
surgery. Weight loss of ≥5 % (malnutrition) was observed in
51 % of patients (25/49) after CRT. Malnutrition at surgery
was noted in 29 % of patients (14/49). Most of them (13/49)
sustained malnutrition since after CRT.
Relationship between malnutrition and adverse
effects/efficacy
Loss of appetite was significantly associated with malnu-
trition after CRT (P< 0.0001) and at surgery (P= 0.011)
(Table 2). However, diarrhea was significantly associated
with malnutrition after CRT (P< 0.05), but not with mal-
nutrition at surgery. Hematological toxicities or histologi-
cal grade (CRT efficacy) was not significantly associated
with malnutrition after CRT or at surgery (Table 2). Other
non-hematological grade 3 and 4 toxicities included
Int J Colorectal Dis (2016) 31:877–884 879
peripheral artery ischemia (one patient), pneumonia (one
patient), and gastric perforation (one patient).
In total, 63 % (31/49) of patients received the sched-
uled dose of chemotherapy. Malnutrition after CRT was
significantly associated with completion of chemotherapy
(P= 0.022): 79 % (19/24) of patients without malnutri-
tion received the complete dose of chemotherapy, where-
as 48 % (12/25) of patients with malnutrition received
the complete dose of chemotherapy (Table 2). These re-
sults indicated that severe appetite loss and diarrhea in-
duced by CRT resulted in malnutrition and decreased
dose intensity.
Table 1 Characteristics of the
patients (N= 110) Patient characteristics CRT(+) CRT(−) P CRT(+) vs.
(n= 49) (n= 61) CRT(−)
Gender (M/F) 36/13 37/24 0.22
Age 63.1 64.7 0.51
Diabetes mellitus 7 8 1.0
Steroid 4 0 0.04
Smoking 14 7 0.029
ASAPS (1/2/3) 4/37/8 14/32/15 0.033
BMI
On consultation 23.1 22.4 0.35
After CRT 21.7 (P< 0.0001) –
At surgery 22.4 (P= 0.0006) 22.4 0.98
Albumin(g/dL)
On consultation 4.1 4.2 0.17
After CRT 3.3 (P< 0.0001) – –
At surgery 4.0 (P= 0.06) 4.2 0.0032
NRS ≥ 3
On consultation 11 15 0.79
After CRT 29 – –
At surgery 20 15 0.07
AV (mm) 43.1 41.3 0.61
Blood loss (mL) 614 666 0.66
Operation time (min) 279 275 0.80
Miles/Hartman/LAR/ISR 5/0/20/24 15/4/14/28 0.027
T (0 or CR/1/2/3/4) 6/3/10/24/6 2/13/12/28/6 0.11
N (0/1/2) 38/8/3 36/16/9 0.11
Stage (0 or CR/I/II/III/IV) 6/9/22/8/4 2/19/14/18/8 0.022
SSI 17 (34.7 %) 12 (19.7 %) 0.076
Anastomotic leakage 12 (27.3 %) 4 (9.5 %) 0.03
Adjuvant therapy in stages 0–1 5 (33.3 %) 0 (0 %) 0.004
Adjuvant therapy in stage 2 9 (40.9 %) 3 (21.4 %) 0.22
Adjuvant therapy in stage 3 6 (75 %) 12 (66.7 %) 0.67
Events in stages 0–3 13 (28.9 %) 13 (24.5 %) 0.79
Recurrence in stages 0–3 12 (26.7 %) 8 (15.1 %) 0.16
CRT chemoradiotherapy, ASAPS American Society of Anesthesiologists Physical Status, BMI body mass index,
NRS nutritional risk screening, AV distance from the anal verge, LAR low anterior resection, ISR intersphincter
resection, SSI surgical site infection
Fig. 1 Changes in weight during the period between completion of
chemoradiotherapy (After CRT) and surgery (At surgery)
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Incidence and treatment of anastomotic leakage
Eighty-six patients who had undergone low anterior or
intersphincteric resection (44 patients who did receive CRT
and 42 patients who did not) were assessed for anastomotic
leakage (Table 1). The incidence of AL was significantly
greater (27.3 %) in CRT(+) than in CRT(−) patients (9.5 %).
Six of 12 patients with AL in the CRT(+) group required no
further treatment. The symptoms of three of the other six re-
solvedwith antibiotics; the remaining three underwent surgery
for peritonitis. Of four patients with AL in the CRT(−) group,
two required no further treatment and the other two received
antibiotics.
Risk factors associated with anastomotic leakage
Risk factors associated with AL were further analyzed in a
subgroup of 86 patients with anastomoses consisting of 44
CRT(+) and 42 CRT(−) patients. In univariate analysis,
CRT, serum albumin concentration at consultation <3.5 g/
dL, and malnutrition at surgery were significantly associated
with AL (Table 3). In subsequent multivariate analysis using
the factors with less than 0.1 of the P value, malnutrition at
surgery was identified as an independent risk factor for AL in
patients who received CRT (Table 3). However, CRT and
albumin concentration at consultation <3.5 g/dL were not sig-
nificant independent risk factors for ALwhen all patients were
analyzed.
Oncological outcomes
Figure 2 shows that AL was a significant prognostic factor in
CRT(+) (n= 36, P= 0.004). DFS at 2 years was 22 % in
CRT(+) patients with AL and 89 % in CRT(+) patients with-
out AL. When stage 0 patients were included, DFS at 2 years
was 44% in CRT(+) patients with AL.Malnutrition at surgery
was not a significant prognostic factor for AL (P=0.08).
Five of ten patients with AL developed recurrence (one
stage 1, three stage 2, and one stage 3). Two stage 2 and one
stage 3 patients received adjuvant chemotherapy. Five patients
without recurrences received no adjuvant chemotherapy.
Discussion
In this study, we evaluated malnutrition at three different time
points (on presentation, after CRT, and before surgery) using
criteria other than those of the CTCAE. We defined malnutri-
tion as 5 % weight loss compared with before CRT and found
that malnutrition in patients with rectal cancer receiving CRT
is common and that sustained malnutrition is associated with
AL. BMI and serum albumin concentrations were significant-
ly reduced following CRT, although serum albumin concen-
trations recovered during the following 6–8 weeks. NRS also
deteriorated with CRT; however, malnutrition defined as NRS
≥3 was not associated with AL. These results demonstrate that
Table 2 Relationship between
malnutrition and side effects/
efficacy (N= 49)
Factors Grade Malnutrition after CRT Malnutrition at surgery
Yes/no (−) (+) P (−) (+) P
Appetite loss 0 21 0 <0.0001 20 1 0.011
1 1 12 6 7
2 2 9 7 4
3 0 4 2 2
Diarrhea 0 14 11 0.033 16 9 0.18
1 3 3 5 1
2 6 2 8 0
3 1 9 6 4
Hematological toxicities 0 3 4 0.37 5 2 0.26
1 8 5 11 2
2 8 13 13 8
3 5 2 6 1
4 0 1 0 1
Complete dose intensity Yes 19 12 0.022 25 6 0.06
No 5 13 10 8
Histological response 1 12 14 0.51 17 9 0.47
2 10 7 14 3
3 2 4 4 2
CRT chemoradiotherapy
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CRT for rectal cancer affects nutritional status adversely and
some patients still have malnutrition 6–8 weeks after CRT.
Malnutrition has been recognized as a risk factor for post-
operative complications and oncological outcomes [6–8].
However, in rectal cancer patients, malnutrition associated
with CRT has not been recognized as a common adverse effect
[19, 21]. This may be partly because adverse events associated
with CRT are usually evaluated by CTCAE, in which severe
Table 3 Characteristics of the patients with or without anastomosis and univariate/multivariate logistic regression analysis of risk factors associated
with anastomotic leakage (N = 86)
Factors AL(+) AL(−) Univariate analysis Multivariate analysis
All patients CRT(+) patients
(N= 16) (N= 70) Odds ratio P Odds ratio P Odds ratio P
Age ≥75 3 10 1.4 0.65
Sex (male) 10 53 0.53 0.29
Diabetes mellitus 4 9 2.3 0.22
Steroid 2 1 9.9 0.07 3.8 0.31 3.9 0.38
Smoking 2 18 0.41 0.27
CRT (N= 44) 12 32 3.6 0.03 3.3 0.056
Albumin on consultation <3.5 g/dL 3 2 7.8 0.03 1.1 0.95 1.3 0.84
Albumin at surgery <3.5 g/dL 1 4 1.1 0.93
Malnutrition after CRT 7 14 1.8 0.39
Malnutrition at surgery 6 5 5.4 0.024 6.3 0.02
ASAPS= 3 5 9 3.1 0.08 2.8 0.17 4.6 0.14
BMI underweight on consultation 1 7 0.6 0.8
BMI underweight at surgery 2 7 1.3 0.49
NRS ≥ 3 on consultation 3 13 1.0 0.99
NRS ≥ 3 after CRT 8 17 1.8 0.42
NRS ≥ 3 at surgery 7 16 2.6 0.1
Blood loss >500 mL 9 28 1.9 0.24
Operation time >5 h 8 21 2.3 0.14
AV< 40 mm (N= 29) 5 24 0.9 0.82
Stage ≥ 2 (N= 52) 12 40 2.3 0.18
AL anastomotic leakage, CRT chemoradiotherapy, BMI body mass index, NRS nutritional risk screening, AV distance from the anal verge, ASAPS
American Society of Anesthesiologists Physical Status
Fig. 2 Survival curves by the Kaplan-Meier method for patients with
stage 1–3 rectal cancer who had anastomoses constructed. a Patients
who underwent both CRT and surgery (CRT(+)) according to the
presence (+) or absence (−) of anastomotic leakage. b Patients who
underwent both CRT and surgery (CRT(+)) according to the presence
(+) or absence (−) of malnutrition at surgery. DFS disease-free survival
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(grade 3) weight loss is defined as 20 % weight loss during
CRTor the necessity for total parenteral nutrition or tube feed-
ing. It seems close to impossible that grade 3 body weight loss
could occur during the 5 weeks of our CRT protocol.
In our study, the incidence of AL in CRT(+) patients
was significantly higher (27.3 %) than in CRT(−) patients
(9.5 %). Although this percentage is higher than in previ-
ous studies, this retrospective case series included patients
with factors that made them unsuitable for admission to a
prospective clinical trial (four patients were receiving ste-
roids and two patients had a history of other cancer within
the previous 5 years).
The mean distance from the anal verge (about 4 cm) was
smaller than in previous studies; more than half the patients
underwent intersphincter resection [3–5]. Tumor location and
difficulty of anastomotic procedure are reportedly associated
with incidence of AL [3]. Therefore, we consider these factors
to account for our high incidence of AL. Schiffmann et al.
reported the same incidence of AL in a retrospective study
[22]. Based on our data, we recommend defunctioning stomas
after CRT in patients who have undergone low rectal cancer
surgery [23].
Our sample was small and the data were assessed retro-
spectively in a single institute. The incidence of malnutrition
and adverse events in patients subjected to the protocol used in
this study seems relatively high compared with previous re-
ports. Therefore, in October 2013, we started a phase II trial
using irinotecan with S-1 and RT for rectal cancer (SAMRAI-
2 trial, UMIN000011115) based on the findings of the present
study. In this new trial, we will assess the relationships be-
tween nutritional indicators and adverse effects, postoperative
complications, and DFS.
Nutritional support before gastrointestinal surgery is rec-
ommended for patients at severe nutritional risk but is contro-
versial for patients without clinical evidence of malnutrition
[9, 10, 24–26].
Our study will encourage evaluating the nutritional status
of rectal cancer patients receiving CRT by criteria other than
those of the CTCAE and providing nutritional support for
patients with malnutrition to reduce the incidence of AL.
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